UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN

Their core work

Universitätsklinikum Schleswig-Holstein (UKSH) is one of Germany's largest university hospitals, operating across two campuses in Kiel and Lübeck. Their H2020 portfolio centers on translational medicine — moving laboratory discoveries into clinical practice, particularly in neurodegenerative diseases, cancer diagnostics, and rare diseases. They bring clinical infrastructure, patient cohorts, and medical expertise to EU consortia, serving as the bridge between basic research and bedside application. Their recent work shows a strong push into precision medicine through next-generation sequencing and liquid biopsy technologies for cancer detection.

What they specialise in

How they've shifted over time

In their early H2020 phase (2015–2018), UKSH focused on classical clinical research in neurodegenerative diseases — iron chelation trials for Parkinson's, systems medicine approaches to mitochondrial dysfunction, and glycosylation research in colorectal cancer. From 2019 onward, a clear shift occurred toward precision medicine technologies: next-generation sequencing workflows, liquid biopsy for multi-cancer detection, and digital health endpoints. This evolution mirrors the broader clinical medicine trend from hypothesis-driven trials toward data-driven, technology-enabled diagnostics and monitoring.

UKSH is moving toward technology-driven precision medicine — particularly NGS-based cancer diagnostics and digital biomarkers — positioning them as a clinical validation partner for diagnostic technology developers.

How they like to work

UKSH predominantly joins consortia as a participant or third party rather than leading them, reflecting the typical role of a university hospital contributing clinical expertise and patient access to larger research networks. They coordinated only one project (DeteCTCs), but it was a high-value innovation action, suggesting growing ambition in leading translational projects. With 255 unique consortium partners across 37 countries, they operate within large, well-connected European networks rather than tight, repeated collaborations.

UKSH has collaborated with 255 unique partners across 37 countries, indicating broad pan-European reach typical of large clinical consortia. Their network spans academic hospitals, research institutes, and industry partners across virtually all EU member states and associated countries.

What sets them apart

UKSH combines the clinical infrastructure of one of northern Germany's largest university hospitals with active engagement in precision medicine and digital health research. Their dual strength in neurodegenerative diseases and cancer diagnostics — especially liquid biopsy — makes them a rare partner who can offer both patient cohorts and clinical validation capacity. For companies developing diagnostic tools or digital health solutions, UKSH provides the clinical environment needed to move from prototype to regulatory-grade evidence.

Highlights from their portfolio

• IDEA-FAST
  Largest single funding (EUR 3.4M) — developing digital endpoints for chronic disease monitoring, representing UKSH's biggest commitment to digital health.
• DeteCTCs
  Only project where UKSH served as coordinator (EUR 877K) — a multi-cancer liquid biopsy test for early detection, signaling their leadership ambition in precision oncology.
• Instand-NGS4P
  Pre-commercial procurement project standardizing NGS workflows for personalized cancer therapy across pediatric and adult patients — directly bridges research and clinical implementation.